Prognostic Impact of mRNA Expression Levels of HER1–4 (ERBB1–4) in Patients with Locally Advanced Rectal Cancer

Figure 3

(a) Kaplan-Meier curve for overall survival (OS) according to the mRNA status of EGFR (ERBB1). The predictive values for EGFR (ERBB1) high and low expression were estimated using the partitioning test. Five-year overall survival for low EGFR (ERBB1) expression was 76%, for high EGFR expression 60%; . (b) Kaplan-Meier curve for disease-free survival (DFS) according to the mRNA status of EGFR (ERBB1). The predictive values for EGFR (ERBB1) high and low expression were estimated using the partitioning test. Five-year disease-free survival for low EGFR (ERBB1) expression was 71%, for high EGFR (ERBB1) expression 13%; . (c) Kaplan-Meier curve for overall survival (OS) according to the mRNA status of ERBB2 (HER2). The predictive values for ERBB2 (HER2) high and low expression were estimated using the partitioning test. Five-year overall survival for low HER2 (ERBB2) expression was 59%, for high HER2 (ERBB2) expression 89%; . (d) Kaplan-Meier curve for disease-free survival (DFS) according to the mRNA status of ERBB2 (HER2). The predictive values for ERBB2 (HER2) high and low expression were estimated using the partitioning test. Five-year overall survival for low HER2 (ERBB2) expression was 56%, for high HER2 (ERBB2) expression 70%; . (e) Kaplan-Meier curve for overall survival (OS) according to the mRNA status of MKI67. The predictive values for MKI67 high and low expression were estimated using the partitioning test. Five-year overall survival for low MKI67 expression was 75%, for high MKI67 expression 55%; . (f) Kaplan-Meier curve for disease-free survival (DFS) according to the mRNA status of MKI67. The predictive values for MKI67 high and low expression were estimated using the partitioning test. Five-year overall survival for low MKI67 expression was 39%, for high MKi67 expression 70%; .

(a)

(b)

(c)

(d)

(e)

(f)